Aquestive Therapeutics Balance Sheet
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics financial position
At the end of fiscal 2025, Aquestive Therapeutics reported total assets of $160.4 million, up 58.2% from a year earlier against total liabilities of $194.1 million. Shareholders' equity was negative at -$33.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $121.2 million in cash and equivalents against $37.5 million of debt, a net cash position of $83.7 million.
The current ratio (current assets divided by current liabilities) was 3.14, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Aquestive Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 121.17M | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M | 49.33M | 60.60M | 17.38M |
| Receivables | 17.76M | 7.34M | 8.47M | — | — | — | — | — | 6.18M |
| Inventory | 6.17M | 6.04M | 6.77M | 5.78M | 4.04M | 2.46M | 2.86M | 5.44M | 4.01M |
| Total Current Assets | 149.27M | 88.22M | 40.97M | 39.89M | 47.26M | 44.63M | 68.31M | 74.20M | 28.16M |
| Property, Plant & Equipment | 3.89M | 3.80M | 4.18M | 4.08M | 5.05M | 6.87M | 9.73M | 12.21M | 13.46M |
| Intangible Assets | 0 | 0 | 1.28M | 1.44M | 51.00K | 102.00K | 153.00K | 204.00K | 254.00K |
| Total Assets | 160.43M | 101.42M | 57.42M | 57.07M | 61.99M | 62.88M | 78.48M | 86.85M | 43.12M |
| Accounts Payable | 29.86M | 10.29M | 8.93M | 9.95M | 8.31M | 7.09M | 12.27M | 20.44M | 9.60M |
| Short-Term Debt | 9.99M | — | — | — | — | — | — | — | — |
| Total Current Liabilities | 47.61M | 18.86M | 18.31M | 39.53M | 21.96M | 21.10M | 18.55M | 32.95M | 15.35M |
| Long-Term Debt | 27.52M | 32.50M | 27.51M | 33.45M | — | 51.50M | 70.00M | — | — |
| Total Liabilities | 194.09M | 161.58M | 163.91M | 175.62M | 144.13M | 111.38M | 84.60M | 76.77M | 69.61M |
| Shareholders' Equity | -33.66M | -60.16M | -106.49M | -118.55M | -82.13M | -48.50M | -6.12M | 10.08M | -26.50M |
| Retained Earnings | -447.00M | -363.21M | -319.08M | -311.21M | -256.80M | -186.26M | -130.47M | -61.38M | -120.09M |
| Total Debt | 37.51M | 32.50M | 27.51M | 33.45M | — | 51.50M | 70.00M | — | — |
| Net Cash (Debt) | 83.66M | 39.05M | -3.64M | -6.17M | 28.02M | -19.69M | -20.67M | 60.60M | 17.38M |
| Shares Outstanding | 122.04M | 91.41M | 68.53M | 54.83M | 41.23M | 34.57M | 33.56M | 24.96M | — |
This table shows 9 annual periods of Aquestive Therapeutics's balance sheet, from FY 2025 back to FY 2017, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AQST's reporting calendar. What is a balance sheet?